WO2023120368A1 - Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid - Google Patents
Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid Download PDFInfo
- Publication number
- WO2023120368A1 WO2023120368A1 PCT/JP2022/046213 JP2022046213W WO2023120368A1 WO 2023120368 A1 WO2023120368 A1 WO 2023120368A1 JP 2022046213 W JP2022046213 W JP 2022046213W WO 2023120368 A1 WO2023120368 A1 WO 2023120368A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ergothioneine
- eicosapentaenoic
- eicosapentaenoic acid
- salt
- acid
- Prior art date
Links
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 171
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 title claims abstract description 113
- 229940093497 ergothioneine Drugs 0.000 title claims abstract description 108
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 92
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 150000003839 salts Chemical class 0.000 title claims abstract description 75
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 31
- 229930195729 fatty acid Natural products 0.000 claims description 31
- 239000000194 fatty acid Substances 0.000 claims description 31
- 150000004665 fatty acids Chemical class 0.000 claims description 31
- 239000000470 constituent Substances 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000014102 seafood Nutrition 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 8
- 235000021323 fish oil Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 240000002769 Morchella esculenta Species 0.000 description 3
- 235000002779 Morchella esculenta Nutrition 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- -1 organic acid salts Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 244000191482 Cantharellus cibarius Species 0.000 description 2
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- 235000007710 Grifola frondosa Nutrition 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001491670 Labyrinthula Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 241000222351 Pleurotus cornucopiae Species 0.000 description 1
- 241001274189 Pomatomus saltatrix Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to oral compositions containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid.
- the present invention also relates to the use of at least one eicosapentaenoic acid for suppressing the bitterness derived from ergothioneine or its salt.
- the present invention relates to a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids.
- Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability.
- Patent Document 1 reports immune response activation cytokine production promotion action and the like.
- ergothioneine has attracted attention as a food, cosmetic, and pharmaceutical product because of its various physiological activities.
- EPA eicosapentaenoic acid
- Patent Document 2 discloses a pharmaceutical composition containing EPA and nicotinic acid.
- ergothioneine since ergothioneine has useful physiological activities, foods such as supplements containing ergothioneine or salts thereof are useful for maintaining or promoting health.
- ergothioneine or a salt thereof has a unique flavor, particularly an unpleasant bitterness that stings the tongue (bitterness), and there is room for improvement in making it an oral composition.
- Foods such as supplements containing EPA are similarly useful, but there is a problem that EPA and its derivatives have an unpleasant flavor (smell). . Therefore, an oral composition containing ergothioneine or a salt thereof and an eicosapentaenoic acid can be expected to have various useful effects, but is thought to have problems of bitterness and odor.
- An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid, in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are reduced.
- Another object of the present invention is to provide use of at least one kind of eicosapentaenoic acid for suppressing the bitterness derived from ergothioneine or a salt thereof.
- the present invention provides a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids in an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid.
- the present inventors found that when ergothioneine or a salt thereof and at least one eicosapentaenoic acid are combined in a specific weight ratio, bitterness derived from ergothioneine or a salt thereof and bitterness derived from eicosapentaenoic acids It has been found that the odor of can be effectively suppressed.
- the present invention includes the following oral compositions and the like.
- composition according to [1] above, wherein the eicosapentaenoic acids are selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
- the compound containing eicosapentaenoic acid as a constituent fatty acid is a triglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, a diglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, and the constituent fatty acid is eicosapentaene.
- composition according to any one of [5] The composition according to any one of [1] to [4] above, wherein component (B) is derived from seafood.
- component (B) is derived from seafood.
- component (B) eicosapentaene A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids, wherein the weight ratio ((B)/(A)) of acid conversion) is adjusted to 0.5 to 15.
- an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are reduced.
- use of at least one kind of eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof can be provided.
- a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids in an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid be able to.
- the oral composition of the present invention (hereinafter also referred to as “the composition of the present invention") comprises the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one
- the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15.
- Ergothioneine is a kind of sulfur-containing amino acid.
- ergothioneine is preferably L-ergothioneine.
- the salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and drink, and may be either an acid salt or a basic salt.
- Acid salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates; Examples include organic acid salts such as acid salts and propionate salts.
- Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts;
- Ergothioneine or a salt thereof is not at all limited by its form, production method, and the like. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from natural products. A large amount of L-ergothioneine is contained in Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom belonging to the genus Pleurotus of the Oysteraceae family.
- Golden/Yellow Oyster Mushroom scientific name: Pleurotus cornucopiae var. citrinopileatus
- L-ergothioneine is found in white button mushrooms, crimini mushrooms, portabella mushrooms and other mushrooms (scientific name: Agaricus bisporus), gray oyster mushrooms (scientific name: Pleurotus ostreatus), shiitake mushrooms (scientific name: Lentinula edodes), maitake mushrooms (Scientific name: Grifola frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybeaegerita), Chanterelle (Scientific name: Cantharellus cibarius), Porcini Name: Boletus edulis), morels ( It is also contained in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta).
- L-ergothioneine When L-ergothioneine is obtained from a natural product, it is preferably extracted from Pleurotus cornucopia. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
- composition of the present invention contains ergothioneine or a salt thereof and at least one eicosapentaenoic acid in the above ratio, thereby reducing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the eicosapentaenoic acid. be. This facilitates continuous intake of ergothioneine or a salt thereof and eicosapentaenoic acids.
- eicosapentaenoic acids eicosapentaenoic acid (free eicosapentaenoic acid), salts thereof and derivatives thereof can be used.
- Eicosapentaenoic acids may be used singly or in combination of two or more.
- derivatives of eicosapentaenoic acid for example, a compound having a structure in which eicosapentaenoic acid is bound and a compound capable of separating eicosapentaenoic acid by hydrolysis can be used.
- Compounds that can separate eicosapentaenoic acid by hydrolysis include compounds containing eicosapentaenoic acid as a constituent fatty acid.
- the eicosapentaenoic acids used in the present invention are preferably selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
- Salts of eicosapentaenoic acid include, for example, calcium salts and sodium salts.
- Compounds containing eicosapentaenoic acid as a constituent fatty acid include triglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, and eicosapentaenoic acid as the constituent fatty acid.
- a compound selected from the group consisting of monoglycerides, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid. is preferred.
- the eicosapentaenoic acids are more preferably triglycerides, diglycerides and phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and more preferably triglycerides and diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid.
- Particularly preferred are triglycerides in which part or all of the constituent fatty acids are eicosapentaenoic acid.
- the eicosapentaenoic acids used in the present invention are not limited in any way by their forms, production methods, etc. Chemically synthesized products may be used, and those derived from natural products and genetically modified organisms (Escherichia coli, yeast, Plants, etc.) may also be used. Examples of those derived from natural products include those derived from fish and shellfish, algae, fungi (labyrinthula, etc.), and plants (marcella, etc.) that have the ability to produce EPA. Among them, eicosapentaenoic acids are preferably derived from fish and shellfish.
- eicosapentaenoic acids extracted and/or purified from raw materials such as natural products containing eicosapentaenoic acids may be used, or the raw materials may be used as they are and the eicosapentaenoic acids may be contained in the composition.
- Raw materials containing eicosapentaenoic acids include, for example, edible oils and fats such as oils and fats extracted from fish oils, eggs, meats, milks and algae.
- the fish oil containing eicosapentaenoic acids is preferably a fish oil concentrated so that the content of eicosapentaenoic acids (eicosapentaenoic acid equivalent) is 5% by weight or more, preferably 10% by weight or more, more preferably 20% by weight or more.
- eicosapentaenoic acids extracted and/or purified from fish oil containing eicosapentaenoic acids may be used, or the fish oil may be used as it is.
- the oral composition of the invention contains fish oil, and the eicosapentaenoic acids may be part of the fish oil.
- the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15.
- the weight ratio is preferably 1-15, more preferably 2-14.
- the amount in terms of ergothioneine or a similar expression means the amount when the component (A) is ergothioneine, and when the component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
- the amount in terms of eicosapentaenoic acid or a similar expression means the amount when the component (B) is free EPA, and when the component (B) is not free EPA, saponification treatment or enzyme It means the amount converted to free EPA by liberating EPA by treatment. When two or more kinds of eicosapentaenoic acids are contained, it is the total of these.
- the content of ergothioneine or a salt thereof contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
- the content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 1% by weight or more in terms of ergothioneine in the composition. is more preferably 1.5% by weight or more, preferably 50% by weight or less, more preferably 30% by weight or less, even more preferably 20% by weight or less, and particularly preferably 10% by weight or less.
- the content of ergothioneine or a salt thereof is preferably 0.1 to 50% by weight, more preferably 0.5 to 30% by weight, and 1 to 20% by weight in terms of ergothioneine in the composition of the present invention. is more preferred, and 1.5 to 10% by weight is particularly preferred.
- the content of ergothioneine can be measured by a high performance liquid chromatography (HPLC) method.
- the content of the eicosapentaenoic acids contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like. When two or more kinds of eicosapentaenoic acids are contained, the above content is the total content thereof.
- the content of eicosapentaenoic acid can be measured by a gas chromatography (GC) method.
- the content of ergothioneine or a salt thereof is preferably 1 to 100 mg, more preferably 2 to 50 mg, more preferably 5 to 25 mg in terms of ergothioneine per day for adults. more preferably 5 to 20 mg, particularly preferably 5 to 20 mg.
- the content of eicosapentaenoic acids in the composition of the present invention is preferably 10 to 2500 mg, more preferably 25 to 1000 mg, more preferably 50 to 500 mg in terms of eicosapentaenoic acid per day for adults. is more preferable.
- Ergothioneine or its salts and eicosapentaenoic acids are compounds that are contained in natural products and foods and drinks and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or its salts and eicosapentaenoic acids, for example, are considered to be ingested every day without any problem. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or a salt thereof and has reduced odor derived from eicosapentaenoic acids, and is easy to ingest.
- ergothioneine or a salt thereof is known to exhibit various physiological activities and health functions.
- UV absorption effect, melanin production inhibitory effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation inhibitory effect, skin sagging inhibitory effect, autophagy promoting effect, etc. are known. Therefore, the composition of the present invention is used for antioxidant, brain function improvement, anti-aging, eye disease, whitening, ultraviolet absorption, suppression of melanin production, elimination of reactive oxygen species, and inhibition of elastase activity. , for suppressing wrinkle formation, for suppressing skin sagging, for promoting autophagy, and the like.
- Eicosapentaenoic acids are known to exert various health functions such as anti-inflammatory effect, blood triglyceride-reducing effect and anti-allergic effect. Since the composition of the present invention contains eicosapentaenoic acids, it can also be used to obtain the above-mentioned effects exhibited by eicosapentaenoic acids.
- compositions of the present invention can be applied for either therapeutic use (medical use) or non-therapeutic use (non-medical use).
- Non-therapeutic is a concept that does not involve medical intervention, i.e. human surgery, treatment or diagnosis.
- the composition of the present invention can be in the form of foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
- the composition of the present invention may be a material or formulation that is used by being blended in foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
- the composition of the present invention is an oral composition, and specific examples of the oral composition include food and drink, oral pharmaceuticals, quasi-drugs, feeds, etc., preferably food and drink or oral It is a pharmaceutical, more preferably a food or drink.
- composition of the present invention can contain optional additives and optional components as long as the effects of the present invention are not impaired.
- additives and ingredients can be selected according to the form of the composition, etc., and those generally usable for oral compositions such as food and drink, pharmaceuticals, quasi-drugs, and feeds can be used.
- a fat containing a fatty acid other than eicosapentaenoic acid or a fat containing no eicosapentaenoic acid can be added.
- the weight ratio of EPA in the total fatty acids constituting the fats and oils is preferably 5% by weight or more, more preferably 10% by weight or more, and still more preferably 15% by weight or more, Particularly preferably, it is 20% by weight or more.
- the n-3 ( ⁇ 3) fatty acid has the highest weight ratio of EPA.
- the method for producing the composition of the present invention is not particularly limited. It can be produced by blending. (A) ergothioneine or a salt thereof, and (B) in the preparation of an oral composition containing at least one eicosapentaenoic acid, component (B) (eicosapentaenoic acid equivalent) relative to component (A) (ergothioneine equivalent) By adjusting the weight ratio ((B)/(A)) to 0.5 to 15, it is possible to obtain an oral composition in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are suppressed. can.
- Adjustment of the weight ratio can be performed by adding component (A) and/or component (B), for example.
- component (B) eicosapentaenoic acid equivalent
- component (B) eicosapentaenoic acid equivalent
- component (B) in terms of eicosapentaenoic acid
- fish oil containing the eicosapentaenoic acids described above may be incorporated in the preparation of oral compositions. Part or all of the eicosapentaenoic acids may be incorporated into the composition as part of the fish oil.
- the manufacturing method is not particularly limited, and it can be manufactured by a general method.
- the composition of the present invention may consist of ergothioneine or a salt thereof and eicosapentaenoic acids.
- the form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
- composition of the present invention when used as a food or drink, ergothioneine or a salt thereof and eicosapentaenoic acids are blended with ingredients that can be used for food or drink (e.g., food materials, food additives used as necessary). It can be used as various foods and drinks.
- Food and drink are not particularly limited, and examples thereof include general food and drink, health food, health supplement, health drink, food with function claims, food for specified health use, and food and drink for sick people.
- Health foods, health supplements, foods with function claims, foods for specified health use, etc. are, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used as various formulation forms such as medicines and liquid foods.
- composition of the present invention When the composition of the present invention is used as a drug or quasi-drug, for example, ergothioneine or a salt thereof and eicosapentaenoic acids are blended with a pharmacologically acceptable carrier, additives added as necessary, and the like. It can be used as pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, etc. may be those that can be used for pharmaceuticals or quasi-drugs and are pharmacologically acceptable. One or more of antioxidants, coloring agents and the like can be mentioned. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like.
- feed When the composition of the present invention is used as a feed, ergothioneine or a salt thereof and eicosapentaenoic acids may be added to the feed.
- Feed also includes feed additives. Examples of feeds include livestock feeds for cows, pigs, chickens, sheep, horses, etc.; small animal feeds for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.;
- Subjects to whom the composition of the present invention is ingested or administered are not particularly limited. Humans or non-human mammals are preferred, and humans are more preferred.
- the present invention also includes the following methods.
- component (B) eicosapentaenoic acid equivalent
- component (A) (ergothioneine equivalent) relative to component (A) (ergothioneine equivalent)
- bitterness derived from ergothioneine or a salt thereof and unpleasant flavor (smell) derived from eicosapentaenoic acids can be effectively suppressed.
- the present invention also includes the following uses.
- the weight ratio of at least one eicosapentaenoic acid (eicosapentaenoic acid conversion) to ergothioneine or a salt thereof (ergothioneine conversion) is preferably 0.5-15.
- ergothioneine or salts thereof and eicosapentaenoic acids and preferred embodiments thereof are the same as the compositions of the present invention described above.
- the preferred range of the weight ratio and amount of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is also determined by component (A) in the composition of the present invention. ) (converted to ergothioneine) and the weight ratio of component (B) (converted to eicosapentaenoic acid) and the preferred range of the amount used.
- bitterness derived from ergothioneine or a salt thereof and the odor derived from EPA can be suppressed by the above methods and uses, they may be combined with other bitterness suppression methods and/or odor suppression methods.
- Other methods for suppressing bitterness include, for example, a method of adding a sweetening agent or a corrigent to a bitter component to prepare a formulation, a method of coating a bitter component with sugar coating to form a formulation, or encapsulating the bitter component into a capsule.
- a method of formulation and the like can be mentioned.
- Other odor-suppressing methods include, for example, a method of coating an odorous component with sugar coating to form a formulation, and a method of enclosing in a capsule to form a formulation.
- a range represented by “1-2” means from 1 to 2 and includes 1 and 2.
- the upper limit and the lower limit may be any combination of ranges.
- Ergothioneine Raw material containing 100% L-ergothioneine
- Eicosapentaenoic acids-containing oil Contains 20% by weight of eicosapentaenoic acids in terms of eicosapentaenoic acid, and among the constituent fatty acids, the weight ratio of EPA for n-3 fatty acids fat with the highest
- Examples 1-3 and Comparative Examples 1-2 Flavor evaluation test for oral compositions containing ergothioneine and eicosapentaenoic acids> An oral composition containing ergothioneine and eicosapentaenoic acids was prepared, and sensory evaluation was performed by three panelists skilled in sensory evaluation. Oral compositions of Examples 1 to 3 and Comparative Examples 1 and 2 were prepared using the above (A) and eicosapentaenoic acid-containing fats and oils in the amounts shown in Table 1.
- Each panelist placed the total amount of the prepared oral composition (e.g., 20 mg in Comparative Example 1) directly on the tongue, and measured the intensity of bitterness derived from ergothioneine and the intensity of odor derived from eicosapentaenoic acids according to the following criteria. evaluated.
- Evaluation criteria for bitterness derived from ergothioneine Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the strength of the bitterness derived from ergothioneine felt when material (A) (10 mg) was placed on the tongue was rated as 5 points. Table 1 shows the average values (scores) of the evaluations of the three panelists. When the average value of the evaluation results was 4 points or less, it was evaluated that the bitterness was suppressed.
- Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria.
- the strength of the odor derived from eicosapentaenoic acids felt when the eicosapentaenoic acid-containing oil (10 mg) was placed on the tongue was rated as 5 points.
- Table 1 shows the average values (scores) of the evaluations of the three panelists. When the average value of the evaluation results was 4 points or less, it was evaluated that the odor was suppressed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and at least one eicosapentaenoic acid and in which the bitterness derived from ergothioneine or the salt thereof and the odor derived from the eicosapentaenoic acid are reduced. The present invention pertains to an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof; and (B) at least one eicosapentaenoic acid, wherein the weight ratio of component (B) (in terms of eicosapentaenoic acid) to component (A) (in terms of ergothioneine) [(B)/(A)] is 0.5-1.5.
Description
本発明は、エルゴチオネイン又はその塩と少なくとも１種のエイコサペンタエン酸類とを含有する経口組成物に関する。また、本発明は、少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用に関する。さらに、本発明は、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法に関する。
The present invention relates to oral compositions containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid. The present invention also relates to the use of at least one eicosapentaenoic acid for suppressing the bitterness derived from ergothioneine or its salt. Furthermore, the present invention relates to a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids.
エルゴチオネインは、親水性含硫アミノ酸の一つであり、抗酸化能をはじめとする多様な生理活性を有することが知られている。エルゴチオネインの生理活性に関して、例えば、特許文献１には免疫応答活性化サイトカイン産生促進作用などが報告されている。
エルゴチオネインは、多様な生理活性を有することから、近年、食品用、化粧品用や医薬用として注目されている。 Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports immune response activation cytokine production promotion action and the like.
In recent years, ergothioneine has attracted attention as a food, cosmetic, and pharmaceutical product because of its various physiological activities.
エルゴチオネインは、多様な生理活性を有することから、近年、食品用、化粧品用や医薬用として注目されている。 Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports immune response activation cytokine production promotion action and the like.
In recent years, ergothioneine has attracted attention as a food, cosmetic, and pharmaceutical product because of its various physiological activities.
一方、サバ、サンマ、イワシ等の青魚の魚油に含まれる油脂の脂肪酸成分であるエイコサペンタエン酸（以下ＥＰＡとも言う）も、多くの生理活性を有していることが知られている。ＥＰＡを含有する組成物として、例えば、特許文献２には、ＥＰＡ及びニコチン酸を含有する製薬組成物が開示されている。
On the other hand, it is also known that eicosapentaenoic acid (hereinafter also referred to as EPA), which is a fatty acid component of fats and oils contained in fish oils of blue fish such as mackerel, saury, and sardines, also has many physiological activities. As a composition containing EPA, for example, Patent Document 2 discloses a pharmaceutical composition containing EPA and nicotinic acid.
上述のとおり、エルゴチオネインは有用な生理活性を有しているため、エルゴチオネイン又はその塩を含むサプリメント等の食品は、健康維持又は増進に有用である。しかしながら、エルゴチオネイン又はその塩には独特の香味、特に舌を刺すような不快な苦味（苦み）があり、経口組成物とするうえで改善する余地があった。
また、ＥＰＡを含むサプリメント等の食品も同様に有用であるが、ＥＰＡやその誘導体には不快な香味（臭み）があるという問題があり、やはり経口組成物とするうえで改善する余地があった。
そのため、エルゴチオネイン又はその塩とエイコサペンタエン酸類とを含有する経口組成物には、様々な有用な効果が期待できるものの、苦味の問題と臭みの問題が生じると考えられる。 As described above, since ergothioneine has useful physiological activities, foods such as supplements containing ergothioneine or salts thereof are useful for maintaining or promoting health. However, ergothioneine or a salt thereof has a unique flavor, particularly an unpleasant bitterness that stings the tongue (bitterness), and there is room for improvement in making it an oral composition.
Foods such as supplements containing EPA are similarly useful, but there is a problem that EPA and its derivatives have an unpleasant flavor (smell). .
Therefore, an oral composition containing ergothioneine or a salt thereof and an eicosapentaenoic acid can be expected to have various useful effects, but is thought to have problems of bitterness and odor.
また、ＥＰＡを含むサプリメント等の食品も同様に有用であるが、ＥＰＡやその誘導体には不快な香味（臭み）があるという問題があり、やはり経口組成物とするうえで改善する余地があった。
そのため、エルゴチオネイン又はその塩とエイコサペンタエン酸類とを含有する経口組成物には、様々な有用な効果が期待できるものの、苦味の問題と臭みの問題が生じると考えられる。 As described above, since ergothioneine has useful physiological activities, foods such as supplements containing ergothioneine or salts thereof are useful for maintaining or promoting health. However, ergothioneine or a salt thereof has a unique flavor, particularly an unpleasant bitterness that stings the tongue (bitterness), and there is room for improvement in making it an oral composition.
Foods such as supplements containing EPA are similarly useful, but there is a problem that EPA and its derivatives have an unpleasant flavor (smell). .
Therefore, an oral composition containing ergothioneine or a salt thereof and an eicosapentaenoic acid can be expected to have various useful effects, but is thought to have problems of bitterness and odor.
本発明の目的は、エルゴチオネイン又はその塩由来の苦味及びエイコサペンタエン酸類に由来する臭みが低減された、エルゴチオネイン又はその塩と少なくとも１種のエイコサペンタエン酸類とを含有する経口組成物を提供することである。また、本発明は、少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用を提供することを目的とする。さらに、本発明は、エルゴチオネイン又はその塩と少なくとも１種のエイコサペンタエン酸類とを含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法を提供することを目的とする。
An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid, in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are reduced. be. Another object of the present invention is to provide use of at least one kind of eicosapentaenoic acid for suppressing the bitterness derived from ergothioneine or a salt thereof. Furthermore, the present invention provides a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids in an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid. With the goal.
本発明者らは上記課題を解決すべく鋭意研究した結果、エルゴチオネイン又はその塩と少なくとも１種のエイコサペンタエン酸類とを特定の重量比で組み合わせると、エルゴチオネイン又はその塩由来の苦味及びエイコサペンタエン酸類由来の臭みを効果的に抑制することができることを見出した。
As a result of intensive research to solve the above problems, the present inventors found that when ergothioneine or a salt thereof and at least one eicosapentaenoic acid are combined in a specific weight ratio, bitterness derived from ergothioneine or a salt thereof and bitterness derived from eicosapentaenoic acids It has been found that the odor of can be effectively suppressed.
本発明は、以下の経口組成物等を包含する。
〔１〕下記の成分（Ａ）及び（Ｂ）：（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有し、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が０．５～１５である、経口組成物。
〔２〕上記エイコサペンタエン酸類が、遊離のエイコサペンタエン酸、その塩及びエイコサペンタエン酸を構成脂肪酸に含む化合物からなる群より選択される、上記〔１〕に記載の組成物。
〔３〕上記エイコサペンタエン酸を構成脂肪酸に含む化合物が、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるジグリセリド、構成脂肪酸がエイコサペンタエン酸であるモノグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるリン脂質、構成脂肪酸の一部又は全部がエイコサペンタエン酸である糖脂質及びエイコサペンタエン酸のアルコールエステルからなる群より選択される、上記〔２〕に記載の組成物。
〔４〕成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が、２～２０である、上記〔１〕～〔３〕のいずれかに記載の組成物。
〔５〕成分（Ｂ）が、魚介類由来である、上記〔１〕～〔４〕のいずれかに記載の組成物。
〔６〕飲食品である、上記〔１〕～〔５〕のいずれかに記載の組成物。
〔７〕少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用。
〔８〕（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有する経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を０．５～１５に調整する、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法。 The present invention includes the following oral compositions and the like.
[1] The following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one eicosapentaenoic acid, and a component (in terms of ergothioneine) for component (A) ( B) An oral composition having a weight ratio ((B)/(A)) (eicosapentaenoic acid equivalent) of 0.5 to 15.
[2] The composition according to [1] above, wherein the eicosapentaenoic acids are selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
[3] The compound containing eicosapentaenoic acid as a constituent fatty acid is a triglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, a diglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, and the constituent fatty acid is eicosapentaene. selected from the group consisting of monoglycerides that are acids, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid , the composition according to the above [2].
[4] The above [1] to [3], wherein the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 2 to 20. The composition according to any one of
[5] The composition according to any one of [1] to [4] above, wherein component (B) is derived from seafood.
[6] The composition according to any one of [1] to [5] above, which is a food or drink.
[7] Use of at least one kind of eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof.
[8] In the preparation of an oral composition containing (A) ergothioneine or a salt thereof and (B) at least one eicosapentaenoic acid, component (B) (eicosapentaene A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids, wherein the weight ratio ((B)/(A)) of acid conversion) is adjusted to 0.5 to 15.
〔１〕下記の成分（Ａ）及び（Ｂ）：（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有し、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が０．５～１５である、経口組成物。
〔２〕上記エイコサペンタエン酸類が、遊離のエイコサペンタエン酸、その塩及びエイコサペンタエン酸を構成脂肪酸に含む化合物からなる群より選択される、上記〔１〕に記載の組成物。
〔３〕上記エイコサペンタエン酸を構成脂肪酸に含む化合物が、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるジグリセリド、構成脂肪酸がエイコサペンタエン酸であるモノグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるリン脂質、構成脂肪酸の一部又は全部がエイコサペンタエン酸である糖脂質及びエイコサペンタエン酸のアルコールエステルからなる群より選択される、上記〔２〕に記載の組成物。
〔４〕成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が、２～２０である、上記〔１〕～〔３〕のいずれかに記載の組成物。
〔５〕成分（Ｂ）が、魚介類由来である、上記〔１〕～〔４〕のいずれかに記載の組成物。
〔６〕飲食品である、上記〔１〕～〔５〕のいずれかに記載の組成物。
〔７〕少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用。
〔８〕（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有する経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を０．５～１５に調整する、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法。 The present invention includes the following oral compositions and the like.
[1] The following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one eicosapentaenoic acid, and a component (in terms of ergothioneine) for component (A) ( B) An oral composition having a weight ratio ((B)/(A)) (eicosapentaenoic acid equivalent) of 0.5 to 15.
[2] The composition according to [1] above, wherein the eicosapentaenoic acids are selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
[3] The compound containing eicosapentaenoic acid as a constituent fatty acid is a triglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, a diglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, and the constituent fatty acid is eicosapentaene. selected from the group consisting of monoglycerides that are acids, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid , the composition according to the above [2].
[4] The above [1] to [3], wherein the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 2 to 20. The composition according to any one of
[5] The composition according to any one of [1] to [4] above, wherein component (B) is derived from seafood.
[6] The composition according to any one of [1] to [5] above, which is a food or drink.
[7] Use of at least one kind of eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof.
[8] In the preparation of an oral composition containing (A) ergothioneine or a salt thereof and (B) at least one eicosapentaenoic acid, component (B) (eicosapentaene A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids, wherein the weight ratio ((B)/(A)) of acid conversion) is adjusted to 0.5 to 15.
本発明によれば、エルゴチオネイン又はその塩由来の苦味及びエイコサペンタエン酸類由来の臭みが低減されたエルゴチオネイン又はその塩及び少なくとも１種のエイコサペンタエン酸類を含有する経口組成物を提供することができる。また、本発明によれば、少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用を提供することができる。さらに、本発明によれば、エルゴチオネイン又はその塩及び少なくとも１種のエイコサペンタエン酸類を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法を提供することができる。
According to the present invention, it is possible to provide an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid, in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are reduced. Moreover, according to the present invention, use of at least one kind of eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof can be provided. Furthermore, according to the present invention, there is provided a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids in an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid. be able to.
本発明の経口組成物（以下、「本発明の組成物」ともいう）は、下記の成分（Ａ）及び（Ｂ）：（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有し、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が０．５～１５である。
The oral composition of the present invention (hereinafter also referred to as "the composition of the present invention") comprises the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one The weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15.
エルゴチオネインは、含硫アミノ酸の一種である。本発明において、エルゴチオネインは、好ましくはＬ－エルゴチオネインである。
エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。 Ergothioneine is a kind of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine.
The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and drink, and may be either an acid salt or a basic salt. Acid salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates; Examples include organic acid salts such as acid salts and propionate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts;
エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。 Ergothioneine is a kind of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine.
The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and drink, and may be either an acid salt or a basic salt. Acid salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates; Examples include organic acid salts such as acid salts and propionate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts;
エルゴチオネイン又はその塩は、その形態や製造方法等によって、何ら制限されるものではない。エルゴチオネイン又はその塩は、化学合成品を使用してもよく、天然物から抽出及び精製したものを使用してもよい。Ｌ－エルゴチオネインは、ヒラタケ科ヒラタケ属のキノコであるタモギタケ（Ｇｏｌｄｅｎ／Ｙｅｌｌｏｗ Ｏｙｓｔｅｒ Ｍｕｓｈｒｏｏｍ）（学名：Ｐｌｅｕｒｏｔｕｓ ｃｏｒｎｕｃｏｐｉａｅ ｖａｒ． ｃｉｔｒｉｎｏｐｉｌｅａｔｕｓ）に多く含有される。Ｌ－エルゴチオネインは、ホワイトボタンマッシュルーム、クリミニマッシュルーム、ポータベラ（Ｐｏｒｔａｂｅｌｌａ）マッシュルーム等のツクリタケ（学名：Ａｇａｒｉｃｕｓ ｂｉｓｐｏｒｕｓ）、ヒラタケ（Ｇｒｅｙ Ｏｙｓｔｅｒ Ｍｕｓｈｒｏｏｍ）（学名：Ｐｌｅｕｒｏｔｕｓ ｏｓｔｒｅａｔｕｓ）、シイタケ（学名：Ｌｅｎｔｉｎｕｌａ ｅｄｏｄｅｓ）、マイタケ（学名：Ｇｒｉｆｏｌａ ｆｒｏｎｄｏｓａ）、レイシ（学名：Ｇａｎｏｄｅｒｍａ ｌｕｃｉｄｕｍ）、ヤマブシタケ（学名：Ｈｅｒｉｃｉｕｍ ｅｒｉｎａｃｅｕｓ）、ヤナギマツタケ（学名：Ａｇｒｏｃｙｂｅ ａｅｇｅｒｉｔａ）、アンズタケ（学名：Ｃａｎｔｈａｒｅｌｌｕｓ ｃｉｂａｒｉｕｓ）、ポルチーニ（学名：Ｂｏｌｅｔｕｓ ｅｄｕｌｉｓ）、アミガサダケ（学名：Ｍｏｒｃｈｅｌｌａ ｅｓｃｕｌｅｎｔａ）等のキノコにも含まれる。天然物からＬ－エルゴチオネインを得る場合は、タモギタケから抽出等することが好ましい。エルゴチオネイン又はその塩は、微生物発酵で製造することもできる。エルゴチオネイン又はその塩は、単離されたものであってもよい。
Ergothioneine or a salt thereof is not at all limited by its form, production method, and the like. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from natural products. A large amount of L-ergothioneine is contained in Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom belonging to the genus Pleurotus of the Oysteraceae family. L-ergothioneine is found in white button mushrooms, crimini mushrooms, portabella mushrooms and other mushrooms (scientific name: Agaricus bisporus), gray oyster mushrooms (scientific name: Pleurotus ostreatus), shiitake mushrooms (scientific name: Lentinula edodes), maitake mushrooms (Scientific name: Grifola frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybeaegerita), Chanterelle (Scientific name: Cantharellus cibarius), Porcini Name: Boletus edulis), morels ( It is also contained in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta). When L-ergothioneine is obtained from a natural product, it is preferably extracted from Pleurotus cornucopia. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
本発明の組成物は、エルゴチオネイン又はその塩と、少なくとも１種のエイコサペンタエン酸類とを上記の比率で含有することにより、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みが低減される。このため、エルゴチオネイン又はその塩とエイコサペンタエン酸類との継続的な摂取が容易となる。
The composition of the present invention contains ergothioneine or a salt thereof and at least one eicosapentaenoic acid in the above ratio, thereby reducing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the eicosapentaenoic acid. be. This facilitates continuous intake of ergothioneine or a salt thereof and eicosapentaenoic acids.
エイコサペンタエン酸類としては、エイコサペンタエン酸（遊離のエイコサペンタエン酸）、その塩及びこれらの誘導体を用いることができる。エイコサペンタエン酸類は、１種を単独で使用してもよく、２種以上を組み合わせて使用してもよい。エイコサペンタエン酸の誘導体として、例えば、エイコサペンタエン酸が結合した構造を有する化合物、及び、加水分解によりエイコサペンタエン酸を分離可能とする化合物を利用することができる。加水分解によりエイコサペンタエン酸を分離可能とする化合物として、エイコサペンタエン酸を構成脂肪酸に含む化合物が挙げられる。
本発明で用いるエイコサペンタエン酸類は、遊離のエイコサペンタエン酸、その塩及びエイコサペンタエン酸を構成脂肪酸に含む化合物からなる群より選択されることが好ましい。
エイコサペンタエン酸の塩としては、例えばカルシウム塩、ナトリウム塩等が挙げられる。
エイコサペンタエン酸を構成脂肪酸に含む化合物としては、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるジグリセリド、構成脂肪酸がエイコサペンタエン酸であるモノグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるリン脂質、構成脂肪酸の一部又は全部がエイコサペンタエン酸である糖脂質及びエイコサペンタエン酸のアルコールエステルからなる群より選択される化合物であることが好ましい。
中でも、エイコサペンタエン酸類としては、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、ジグリセリド及びリン脂質がより好ましく、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド及びジグリセリドが更に好ましく、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリドが特に好ましい。 As eicosapentaenoic acids, eicosapentaenoic acid (free eicosapentaenoic acid), salts thereof and derivatives thereof can be used. Eicosapentaenoic acids may be used singly or in combination of two or more. As derivatives of eicosapentaenoic acid, for example, a compound having a structure in which eicosapentaenoic acid is bound and a compound capable of separating eicosapentaenoic acid by hydrolysis can be used. Compounds that can separate eicosapentaenoic acid by hydrolysis include compounds containing eicosapentaenoic acid as a constituent fatty acid.
The eicosapentaenoic acids used in the present invention are preferably selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
Salts of eicosapentaenoic acid include, for example, calcium salts and sodium salts.
Compounds containing eicosapentaenoic acid as a constituent fatty acid include triglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, and eicosapentaenoic acid as the constituent fatty acid. A compound selected from the group consisting of monoglycerides, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid. is preferred.
Among them, the eicosapentaenoic acids are more preferably triglycerides, diglycerides and phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and more preferably triglycerides and diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid. Particularly preferred are triglycerides in which part or all of the constituent fatty acids are eicosapentaenoic acid.
本発明で用いるエイコサペンタエン酸類は、遊離のエイコサペンタエン酸、その塩及びエイコサペンタエン酸を構成脂肪酸に含む化合物からなる群より選択されることが好ましい。
エイコサペンタエン酸の塩としては、例えばカルシウム塩、ナトリウム塩等が挙げられる。
エイコサペンタエン酸を構成脂肪酸に含む化合物としては、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるジグリセリド、構成脂肪酸がエイコサペンタエン酸であるモノグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるリン脂質、構成脂肪酸の一部又は全部がエイコサペンタエン酸である糖脂質及びエイコサペンタエン酸のアルコールエステルからなる群より選択される化合物であることが好ましい。
中でも、エイコサペンタエン酸類としては、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、ジグリセリド及びリン脂質がより好ましく、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド及びジグリセリドが更に好ましく、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリドが特に好ましい。 As eicosapentaenoic acids, eicosapentaenoic acid (free eicosapentaenoic acid), salts thereof and derivatives thereof can be used. Eicosapentaenoic acids may be used singly or in combination of two or more. As derivatives of eicosapentaenoic acid, for example, a compound having a structure in which eicosapentaenoic acid is bound and a compound capable of separating eicosapentaenoic acid by hydrolysis can be used. Compounds that can separate eicosapentaenoic acid by hydrolysis include compounds containing eicosapentaenoic acid as a constituent fatty acid.
The eicosapentaenoic acids used in the present invention are preferably selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
Salts of eicosapentaenoic acid include, for example, calcium salts and sodium salts.
Compounds containing eicosapentaenoic acid as a constituent fatty acid include triglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, and eicosapentaenoic acid as the constituent fatty acid. A compound selected from the group consisting of monoglycerides, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid. is preferred.
Among them, the eicosapentaenoic acids are more preferably triglycerides, diglycerides and phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and more preferably triglycerides and diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid. Particularly preferred are triglycerides in which part or all of the constituent fatty acids are eicosapentaenoic acid.
本発明で用いるエイコサペンタエン酸類は、その形態や製造方法等によって、何ら制限されるものではなく、化学合成品を使用してもよく、天然物に由来するものや遺伝子組み換え生物（大腸菌、酵母、植物等）に由来するものを使用してもよい。天然物に由来するものとして、ＥＰＡを生産する能力を有する魚介類や藻類、菌類（ラビリンチュラ類等）、植物（ゼニゴケ等）に由来するものを挙げることができる。中でも、エイコサペンタエン酸類が魚介類由来であることが好ましい。
また、エイコサペンタエン酸類を含有する天然物等の原料から抽出及び／又は精製したエイコサペンタエン酸類を使用してもよいし、当該原料をそのまま使用してエイコサペンタエン酸類を組成物に含有させてもよい。エイコサペンタエン酸類を含む原料として、例えば、魚油、卵、肉類、乳類や藻類から抽出された油脂等の食用油脂が挙げられる。エイコサペンタエン酸類を含む魚油として、エイコサペンタエン酸類（エイコサペンタエン酸換算）の含有率が５重量％以上、好ましくは１０重量％以上、より好ましくは２０重量％以上となるように濃縮された魚油が好ましい。例えば、エイコサペンタエン酸類を含有する魚油から抽出及び／又は精製したエイコサペンタエン酸類を使用してもよく、当該魚油をそのまま使用してもよい。一態様において、本発明の経口組成物は、魚油を含有し、エイコサペンタエン酸類は、当該魚油の一部であってもよい。 The eicosapentaenoic acids used in the present invention are not limited in any way by their forms, production methods, etc. Chemically synthesized products may be used, and those derived from natural products and genetically modified organisms (Escherichia coli, yeast, Plants, etc.) may also be used. Examples of those derived from natural products include those derived from fish and shellfish, algae, fungi (labyrinthula, etc.), and plants (marcella, etc.) that have the ability to produce EPA. Among them, eicosapentaenoic acids are preferably derived from fish and shellfish.
In addition, eicosapentaenoic acids extracted and/or purified from raw materials such as natural products containing eicosapentaenoic acids may be used, or the raw materials may be used as they are and the eicosapentaenoic acids may be contained in the composition. . Raw materials containing eicosapentaenoic acids include, for example, edible oils and fats such as oils and fats extracted from fish oils, eggs, meats, milks and algae. The fish oil containing eicosapentaenoic acids is preferably a fish oil concentrated so that the content of eicosapentaenoic acids (eicosapentaenoic acid equivalent) is 5% by weight or more, preferably 10% by weight or more, more preferably 20% by weight or more. . For example, eicosapentaenoic acids extracted and/or purified from fish oil containing eicosapentaenoic acids may be used, or the fish oil may be used as it is. In one aspect, the oral composition of the invention contains fish oil, and the eicosapentaenoic acids may be part of the fish oil.
また、エイコサペンタエン酸類を含有する天然物等の原料から抽出及び／又は精製したエイコサペンタエン酸類を使用してもよいし、当該原料をそのまま使用してエイコサペンタエン酸類を組成物に含有させてもよい。エイコサペンタエン酸類を含む原料として、例えば、魚油、卵、肉類、乳類や藻類から抽出された油脂等の食用油脂が挙げられる。エイコサペンタエン酸類を含む魚油として、エイコサペンタエン酸類（エイコサペンタエン酸換算）の含有率が５重量％以上、好ましくは１０重量％以上、より好ましくは２０重量％以上となるように濃縮された魚油が好ましい。例えば、エイコサペンタエン酸類を含有する魚油から抽出及び／又は精製したエイコサペンタエン酸類を使用してもよく、当該魚油をそのまま使用してもよい。一態様において、本発明の経口組成物は、魚油を含有し、エイコサペンタエン酸類は、当該魚油の一部であってもよい。 The eicosapentaenoic acids used in the present invention are not limited in any way by their forms, production methods, etc. Chemically synthesized products may be used, and those derived from natural products and genetically modified organisms (Escherichia coli, yeast, Plants, etc.) may also be used. Examples of those derived from natural products include those derived from fish and shellfish, algae, fungi (labyrinthula, etc.), and plants (marcella, etc.) that have the ability to produce EPA. Among them, eicosapentaenoic acids are preferably derived from fish and shellfish.
In addition, eicosapentaenoic acids extracted and/or purified from raw materials such as natural products containing eicosapentaenoic acids may be used, or the raw materials may be used as they are and the eicosapentaenoic acids may be contained in the composition. . Raw materials containing eicosapentaenoic acids include, for example, edible oils and fats such as oils and fats extracted from fish oils, eggs, meats, milks and algae. The fish oil containing eicosapentaenoic acids is preferably a fish oil concentrated so that the content of eicosapentaenoic acids (eicosapentaenoic acid equivalent) is 5% by weight or more, preferably 10% by weight or more, more preferably 20% by weight or more. . For example, eicosapentaenoic acids extracted and/or purified from fish oil containing eicosapentaenoic acids may be used, or the fish oil may be used as it is. In one aspect, the oral composition of the invention contains fish oil, and the eicosapentaenoic acids may be part of the fish oil.
本発明の組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））は、０．５～１５である。上記重量比が上記範囲であると、成分（Ａ）に由来する苦味を抑制することができる。また、成分（Ｂ）に由来する臭みも抑制することができる。これにより、組成物が摂取しやすいものとなる。上記重量比は、好ましくは１～１５であり、より好ましくは２～１４である。
本明細書中、エルゴチオネイン換算の量又はこれに類する表現は、成分（Ａ）がエルゴチオネインの場合はその量を意味し、成分（Ａ）がエルゴチオネインの塩の場合は、当該塩のモル数に、エルゴチオネインの分子量を乗じて得られる値を意味する。
エイコサペンタエン酸換算の量又はこれに類する表現は、成分（Ｂ）が遊離のＥＰＡである場合にはその量を意味し、成分（Ｂ）が遊離のＥＰＡではない場合には、鹸化処理や酵素処理によりＥＰＡを遊離させ、遊離のＥＰＡとして換算した量を意味する。エイコサペンタエン酸類を２種以上含有する場合は、これらの合計である。 In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15. When the weight ratio is within the above range, bitterness derived from the component (A) can be suppressed. Moreover, the odor derived from the component (B) can also be suppressed. This makes the composition easier to ingest. The weight ratio is preferably 1-15, more preferably 2-14.
In the present specification, the amount in terms of ergothioneine or a similar expression means the amount when the component (A) is ergothioneine, and when the component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
The amount in terms of eicosapentaenoic acid or a similar expression means the amount when the component (B) is free EPA, and when the component (B) is not free EPA, saponification treatment or enzyme It means the amount converted to free EPA by liberating EPA by treatment. When two or more kinds of eicosapentaenoic acids are contained, it is the total of these.
本明細書中、エルゴチオネイン換算の量又はこれに類する表現は、成分（Ａ）がエルゴチオネインの場合はその量を意味し、成分（Ａ）がエルゴチオネインの塩の場合は、当該塩のモル数に、エルゴチオネインの分子量を乗じて得られる値を意味する。
エイコサペンタエン酸換算の量又はこれに類する表現は、成分（Ｂ）が遊離のＥＰＡである場合にはその量を意味し、成分（Ｂ）が遊離のＥＰＡではない場合には、鹸化処理や酵素処理によりＥＰＡを遊離させ、遊離のＥＰＡとして換算した量を意味する。エイコサペンタエン酸類を２種以上含有する場合は、これらの合計である。 In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15. When the weight ratio is within the above range, bitterness derived from the component (A) can be suppressed. Moreover, the odor derived from the component (B) can also be suppressed. This makes the composition easier to ingest. The weight ratio is preferably 1-15, more preferably 2-14.
In the present specification, the amount in terms of ergothioneine or a similar expression means the amount when the component (A) is ergothioneine, and when the component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
The amount in terms of eicosapentaenoic acid or a similar expression means the amount when the component (B) is free EPA, and when the component (B) is not free EPA, saponification treatment or enzyme It means the amount converted to free EPA by liberating EPA by treatment. When two or more kinds of eicosapentaenoic acids are contained, it is the total of these.
本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は特に限定されず、その形態等に応じて設定することができる。
本発明の組成物中のエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、例えば、該組成物中に０．１重量％以上が好ましく、０．５重量％以上がより好ましく、１重量％以上が更に好ましく、１．５重量％以上が特に好ましく、また、５０重量％以下が好ましく、３０重量％以下がより好ましく、２０重量％以下が更に好ましく、１０重量％以下が特に好ましい。一態様において、エルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、本発明の組成物中に０．１～５０重量％が好ましく、０．５～３０重量％がより好ましく、１～２０重量％が更に好ましく、１．５～１０重量％が特に好ましい。
エルゴチオネインの含有量は、高速液体クロマトグラフィー（ＨＰＬＣ）法により測定することができる。 The content of ergothioneine or a salt thereof contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 1% by weight or more in terms of ergothioneine in the composition. is more preferably 1.5% by weight or more, preferably 50% by weight or less, more preferably 30% by weight or less, even more preferably 20% by weight or less, and particularly preferably 10% by weight or less. In one aspect, the content of ergothioneine or a salt thereof is preferably 0.1 to 50% by weight, more preferably 0.5 to 30% by weight, and 1 to 20% by weight in terms of ergothioneine in the composition of the present invention. is more preferred, and 1.5 to 10% by weight is particularly preferred.
The content of ergothioneine can be measured by a high performance liquid chromatography (HPLC) method.
本発明の組成物中のエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、例えば、該組成物中に０．１重量％以上が好ましく、０．５重量％以上がより好ましく、１重量％以上が更に好ましく、１．５重量％以上が特に好ましく、また、５０重量％以下が好ましく、３０重量％以下がより好ましく、２０重量％以下が更に好ましく、１０重量％以下が特に好ましい。一態様において、エルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、本発明の組成物中に０．１～５０重量％が好ましく、０．５～３０重量％がより好ましく、１～２０重量％が更に好ましく、１．５～１０重量％が特に好ましい。
エルゴチオネインの含有量は、高速液体クロマトグラフィー（ＨＰＬＣ）法により測定することができる。 The content of ergothioneine or a salt thereof contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 1% by weight or more in terms of ergothioneine in the composition. is more preferably 1.5% by weight or more, preferably 50% by weight or less, more preferably 30% by weight or less, even more preferably 20% by weight or less, and particularly preferably 10% by weight or less. In one aspect, the content of ergothioneine or a salt thereof is preferably 0.1 to 50% by weight, more preferably 0.5 to 30% by weight, and 1 to 20% by weight in terms of ergothioneine in the composition of the present invention. is more preferred, and 1.5 to 10% by weight is particularly preferred.
The content of ergothioneine can be measured by a high performance liquid chromatography (HPLC) method.
本発明の組成物に含まれるエイコサペンタエン酸類の含有量は特に限定されず、その形態等に応じて設定することができる。
上記含有量は、エイコサペンタエン酸類を２種以上含有する場合は、これらの合計含有量である。エイコサペンタエン酸の含有量は、ガスクロマトグラフィー（ＧＣ）法により測定することができる。 The content of the eicosapentaenoic acids contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
When two or more kinds of eicosapentaenoic acids are contained, the above content is the total content thereof. The content of eicosapentaenoic acid can be measured by a gas chromatography (GC) method.
上記含有量は、エイコサペンタエン酸類を２種以上含有する場合は、これらの合計含有量である。エイコサペンタエン酸の含有量は、ガスクロマトグラフィー（ＧＣ）法により測定することができる。 The content of the eicosapentaenoic acids contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
When two or more kinds of eicosapentaenoic acids are contained, the above content is the total content thereof. The content of eicosapentaenoic acid can be measured by a gas chromatography (GC) method.
本発明の組成物は、エルゴチオネイン又はその塩の含有量が、成人の１日摂取量当たり、エルゴチオネイン換算で１～１００ｍｇであることが好ましく、２～５０ｍｇであることがより好ましく、５～２５ｍｇであることが更に好ましく、５～２０ｍｇであることが特に好ましい。
本発明の組成物は、エイコサペンタエン酸類の含有量が、成人の１日摂取量当たり、エイコサペンタエン酸換算で１０～２５００ｍｇであることが好ましく、２５～１０００ｍｇであることがより好ましく、５０～５００ｍｇであることが更に好ましい。 In the composition of the present invention, the content of ergothioneine or a salt thereof is preferably 1 to 100 mg, more preferably 2 to 50 mg, more preferably 5 to 25 mg in terms of ergothioneine per day for adults. more preferably 5 to 20 mg, particularly preferably 5 to 20 mg.
The content of eicosapentaenoic acids in the composition of the present invention is preferably 10 to 2500 mg, more preferably 25 to 1000 mg, more preferably 50 to 500 mg in terms of eicosapentaenoic acid per day for adults. is more preferable.
本発明の組成物は、エイコサペンタエン酸類の含有量が、成人の１日摂取量当たり、エイコサペンタエン酸換算で１０～２５００ｍｇであることが好ましく、２５～１０００ｍｇであることがより好ましく、５０～５００ｍｇであることが更に好ましい。 In the composition of the present invention, the content of ergothioneine or a salt thereof is preferably 1 to 100 mg, more preferably 2 to 50 mg, more preferably 5 to 25 mg in terms of ergothioneine per day for adults. more preferably 5 to 20 mg, particularly preferably 5 to 20 mg.
The content of eicosapentaenoic acids in the composition of the present invention is preferably 10 to 2500 mg, more preferably 25 to 1000 mg, more preferably 50 to 500 mg in terms of eicosapentaenoic acid per day for adults. is more preferable.
エルゴチオネイン又はその塩及びエイコサペンタエン酸類は、天然物や飲食品に含まれ、食経験がある化合物である。このため安全性の観点から、エルゴチオネイン又はその塩及びエイコサペンタエン酸類は、例えば毎日摂取することにも問題が少ないと考えられる。本発明によれば、安全性が高く、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みが低減されて摂取しやすい組成物を提供することができる。
Ergothioneine or its salts and eicosapentaenoic acids are compounds that are contained in natural products and foods and drinks and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or its salts and eicosapentaenoic acids, for example, are considered to be ingested every day without any problem. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or a salt thereof and has reduced odor derived from eicosapentaenoic acids, and is easy to ingest.
エルゴチオネイン又はその塩は、上述のとおり、多様な生理活性や健康機能を発揮することが知られており、例えば、抗酸化作用、脳機能改善効果、抗老化作用、眼疾患改善効果、美白効果、紫外線吸収効果、メラニン産生抑制効果、活性酸素種の消去作用、エラスターゼ活性阻害効果、シワ形成抑制効果、肌のたるみ抑制効果、オートファジー促進効果等が知られている。
このため、本発明の組成物は、抗酸化用、脳機能改善用、抗老化用、眼疾患用、美白用、紫外線吸収用、メラニン産生抑制用、活性酸素種の消去用、エラスターゼ活性阻害用、シワ形成抑制用、肌のたるみ抑制用、オートファジー促進用等に好適に用いることができる。 As described above, ergothioneine or a salt thereof is known to exhibit various physiological activities and health functions. UV absorption effect, melanin production inhibitory effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation inhibitory effect, skin sagging inhibitory effect, autophagy promoting effect, etc. are known.
Therefore, the composition of the present invention is used for antioxidant, brain function improvement, anti-aging, eye disease, whitening, ultraviolet absorption, suppression of melanin production, elimination of reactive oxygen species, and inhibition of elastase activity. , for suppressing wrinkle formation, for suppressing skin sagging, for promoting autophagy, and the like.
このため、本発明の組成物は、抗酸化用、脳機能改善用、抗老化用、眼疾患用、美白用、紫外線吸収用、メラニン産生抑制用、活性酸素種の消去用、エラスターゼ活性阻害用、シワ形成抑制用、肌のたるみ抑制用、オートファジー促進用等に好適に用いることができる。 As described above, ergothioneine or a salt thereof is known to exhibit various physiological activities and health functions. UV absorption effect, melanin production inhibitory effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation inhibitory effect, skin sagging inhibitory effect, autophagy promoting effect, etc. are known.
Therefore, the composition of the present invention is used for antioxidant, brain function improvement, anti-aging, eye disease, whitening, ultraviolet absorption, suppression of melanin production, elimination of reactive oxygen species, and inhibition of elastase activity. , for suppressing wrinkle formation, for suppressing skin sagging, for promoting autophagy, and the like.
エイコサペンタエン酸類については、抗炎症効果、血中中性脂肪低減効果、抗アレルギー効果等の種々の健康機能を発揮することが知られている。
本発明の組成物は、エイコサペンタエン酸類を含有することから、エイコサペンタエン酸類により発揮される上記の効果を得るために使用することもできる。 Eicosapentaenoic acids are known to exert various health functions such as anti-inflammatory effect, blood triglyceride-reducing effect and anti-allergic effect.
Since the composition of the present invention contains eicosapentaenoic acids, it can also be used to obtain the above-mentioned effects exhibited by eicosapentaenoic acids.
本発明の組成物は、エイコサペンタエン酸類を含有することから、エイコサペンタエン酸類により発揮される上記の効果を得るために使用することもできる。 Eicosapentaenoic acids are known to exert various health functions such as anti-inflammatory effect, blood triglyceride-reducing effect and anti-allergic effect.
Since the composition of the present invention contains eicosapentaenoic acids, it can also be used to obtain the above-mentioned effects exhibited by eicosapentaenoic acids.
本発明の組成物は、治療的用途（医療用途）又は非治療的用途（非医療用途）のいずれにも適用することができる。非治療的とは、医療行為、すなわち人間の手術、治療又は診断を含まない概念である。
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等に配合して使用される素材又は製剤等であってもよい。 The compositions of the present invention can be applied for either therapeutic use (medical use) or non-therapeutic use (non-medical use). Non-therapeutic is a concept that does not involve medical intervention, i.e. human surgery, treatment or diagnosis.
The composition of the present invention can be in the form of foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like. The composition of the present invention may be a material or formulation that is used by being blended in foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等に配合して使用される素材又は製剤等であってもよい。 The compositions of the present invention can be applied for either therapeutic use (medical use) or non-therapeutic use (non-medical use). Non-therapeutic is a concept that does not involve medical intervention, i.e. human surgery, treatment or diagnosis.
The composition of the present invention can be in the form of foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like. The composition of the present invention may be a material or formulation that is used by being blended in foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
本発明の組成物は、経口用の組成物であり、経口組成物として具体的には、飲食品、経口用の医薬品、医薬部外品、飼料等が挙げられ、好ましくは飲食品又は経口用医薬品であり、より好ましくは飲食品である。
The composition of the present invention is an oral composition, and specific examples of the oral composition include food and drink, oral pharmaceuticals, quasi-drugs, feeds, etc., preferably food and drink or oral It is a pharmaceutical, more preferably a food or drink.
本発明の組成物は、本発明の効果を損なわない限り、エルゴチオネイン又はその塩及びエイコサペンタエン酸類に加えて、任意の添加剤、任意の成分を含有することができる。これらの添加剤及び成分は、組成物の形態等に応じて選択することができ、一般的に飲食品、医薬品、医薬部外品、飼料等の経口組成物に使用可能なものが使用できる。
In addition to ergothioneine or a salt thereof and eicosapentaenoic acids, the composition of the present invention can contain optional additives and optional components as long as the effects of the present invention are not impaired. These additives and ingredients can be selected according to the form of the composition, etc., and those generally usable for oral compositions such as food and drink, pharmaceuticals, quasi-drugs, and feeds can be used.
本発明の組成物には、例えば、エイコサペンタエン酸以外の脂肪酸を含有する油脂やエイコサペンタエン酸類を含有していない油脂を添加することもできる。
本発明の組成物が油脂を含有する場合、油脂を構成する全脂肪酸のうち、ＥＰＡの重量割合が、好ましくは５重量％以上、より好ましくは１０重量％以上、更に好ましくは１５重量％以上、特に好ましくは２０重量％以上であることが好ましい。
油脂を構成する全脂肪酸のうち、ｎ－３系（ω３系）脂肪酸については、ＥＰＡの重量割合が最も高いことが好ましい。 To the composition of the present invention, for example, a fat containing a fatty acid other than eicosapentaenoic acid or a fat containing no eicosapentaenoic acid can be added.
When the composition of the present invention contains fats and oils, the weight ratio of EPA in the total fatty acids constituting the fats and oils is preferably 5% by weight or more, more preferably 10% by weight or more, and still more preferably 15% by weight or more, Particularly preferably, it is 20% by weight or more.
Among all the fatty acids that constitute fats and oils, it is preferable that the n-3 (ω3) fatty acid has the highest weight ratio of EPA.
本発明の組成物が油脂を含有する場合、油脂を構成する全脂肪酸のうち、ＥＰＡの重量割合が、好ましくは５重量％以上、より好ましくは１０重量％以上、更に好ましくは１５重量％以上、特に好ましくは２０重量％以上であることが好ましい。
油脂を構成する全脂肪酸のうち、ｎ－３系（ω３系）脂肪酸については、ＥＰＡの重量割合が最も高いことが好ましい。 To the composition of the present invention, for example, a fat containing a fatty acid other than eicosapentaenoic acid or a fat containing no eicosapentaenoic acid can be added.
When the composition of the present invention contains fats and oils, the weight ratio of EPA in the total fatty acids constituting the fats and oils is preferably 5% by weight or more, more preferably 10% by weight or more, and still more preferably 15% by weight or more, Particularly preferably, it is 20% by weight or more.
Among all the fatty acids that constitute fats and oils, it is preferable that the n-3 (ω3) fatty acid has the highest weight ratio of EPA.
本発明の組成物の製造方法は特に限定されず、例えば、（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類を、これらの重量比が上記の範囲となるように配合して製造することができる。（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類を含有する経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を０．５～１５に調整することで、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みが抑制された経口組成物を得ることができる。上記重量比の調整は、例えば、成分（Ａ）及び／又は成分（Ｂ）を添加することで行うことができる。
上記の製造方法において、エルゴチオネイン又はその塩、エイコサペンタエン酸類、これらの好ましい態様は、上述した本発明の組成物と同じである。また、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲も、本発明の組成物における、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲と同じである。
一態様において、経口組成物の製造においては、上記のエイコサペンタエン酸類を含む魚油を配合してもよい。エイコサペンタエン酸類は、その一部又は全部が、魚油の一部として組成物に配合されてもよい。 The method for producing the composition of the present invention is not particularly limited. It can be produced by blending. (A) ergothioneine or a salt thereof, and (B) in the preparation of an oral composition containing at least one eicosapentaenoic acid, component (B) (eicosapentaenoic acid equivalent) relative to component (A) (ergothioneine equivalent) By adjusting the weight ratio ((B)/(A)) to 0.5 to 15, it is possible to obtain an oral composition in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are suppressed. can. Adjustment of the weight ratio can be performed by adding component (A) and/or component (B), for example.
In the production method described above, ergothioneine or a salt thereof, eicosapentaenoic acids, and preferred embodiments thereof are the same as those of the composition of the present invention described above. In addition, the preferred range of the weight ratio and usage amount of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is also a component relative to component (A) (ergothioneine equivalent) in the composition of the present invention. (B) (in terms of eicosapentaenoic acid) is the same as the preferred range of the weight ratio and usage amount.
In one aspect, fish oil containing the eicosapentaenoic acids described above may be incorporated in the preparation of oral compositions. Part or all of the eicosapentaenoic acids may be incorporated into the composition as part of the fish oil.
上記の製造方法において、エルゴチオネイン又はその塩、エイコサペンタエン酸類、これらの好ましい態様は、上述した本発明の組成物と同じである。また、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲も、本発明の組成物における、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲と同じである。
一態様において、経口組成物の製造においては、上記のエイコサペンタエン酸類を含む魚油を配合してもよい。エイコサペンタエン酸類は、その一部又は全部が、魚油の一部として組成物に配合されてもよい。 The method for producing the composition of the present invention is not particularly limited. It can be produced by blending. (A) ergothioneine or a salt thereof, and (B) in the preparation of an oral composition containing at least one eicosapentaenoic acid, component (B) (eicosapentaenoic acid equivalent) relative to component (A) (ergothioneine equivalent) By adjusting the weight ratio ((B)/(A)) to 0.5 to 15, it is possible to obtain an oral composition in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are suppressed. can. Adjustment of the weight ratio can be performed by adding component (A) and/or component (B), for example.
In the production method described above, ergothioneine or a salt thereof, eicosapentaenoic acids, and preferred embodiments thereof are the same as those of the composition of the present invention described above. In addition, the preferred range of the weight ratio and usage amount of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is also a component relative to component (A) (ergothioneine equivalent) in the composition of the present invention. (B) (in terms of eicosapentaenoic acid) is the same as the preferred range of the weight ratio and usage amount.
In one aspect, fish oil containing the eicosapentaenoic acids described above may be incorporated in the preparation of oral compositions. Part or all of the eicosapentaenoic acids may be incorporated into the composition as part of the fish oil.
本発明の組成物を、飲食品、医薬品、医薬部外品、飼料等とする場合、その製造方法は特に限定されず、一般的な方法により製造することができる。一態様において、本発明の組成物は、エルゴチオネイン又はその塩及びエイコサペンタエン酸類からなるものであってもよい。本発明の経口組成物の形態は特に限定されず、固体状（粉末状、顆粒状、タブレット状等）、液状、ペースト状等であってよい。
When the composition of the present invention is used as a food or beverage, a drug, a quasi-drug, a feed, or the like, the manufacturing method is not particularly limited, and it can be manufactured by a general method. In one aspect, the composition of the present invention may consist of ergothioneine or a salt thereof and eicosapentaenoic acids. The form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
例えば本発明の組成物を飲食品とする場合、エルゴチオネイン又はその塩及びエイコサペンタエン酸類に、飲食品に使用可能な成分（例えば、食品素材、必要に応じて使用される食品添加物等）を配合して、種々の飲食品とすることができる。飲食品は特に限定されず、例えば、一般的な飲食品、健康食品、健康補助食品、健康飲料、機能性表示食品、特定保健用食品、病者用飲食品等が挙げられる。上記健康食品、健康補助食品、機能性表示食品、特定保健用食品等は、例えば、細粒剤、錠剤、顆粒剤、散剤、カプセル剤、チュアブル剤、ドライシロップ剤、シロップ剤、液剤、飲料、ドリンク剤、流動食等の各種製剤形態として使用することができる。
For example, when the composition of the present invention is used as a food or drink, ergothioneine or a salt thereof and eicosapentaenoic acids are blended with ingredients that can be used for food or drink (e.g., food materials, food additives used as necessary). It can be used as various foods and drinks. Food and drink are not particularly limited, and examples thereof include general food and drink, health food, health supplement, health drink, food with function claims, food for specified health use, and food and drink for sick people. Health foods, health supplements, foods with function claims, foods for specified health use, etc. are, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used as various formulation forms such as medicines and liquid foods.
本発明の組成物を医薬品又は医薬部外品とする場合、例えば、エルゴチオネイン又はその塩及びエイコサペンタエン酸類に、薬理学的に許容される担体、必要に応じて添加される添加剤等を配合して、各種剤形の医薬品又は医薬部外品とすることができる。そのような担体、添加剤等は、医薬品又は医薬部外品に使用可能な、薬理学的に許容されるものであればよく、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、抗酸化剤、着色剤等の１又は２以上が挙げられる。医薬品又は医薬部外品の経口投与のための剤形としては、液剤、錠剤、散剤、細粒剤、顆粒剤、糖衣錠、カプセル剤、懸濁液、乳剤、チュアブル剤等が挙げられる。
When the composition of the present invention is used as a drug or quasi-drug, for example, ergothioneine or a salt thereof and eicosapentaenoic acids are blended with a pharmacologically acceptable carrier, additives added as necessary, and the like. It can be used as pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, etc. may be those that can be used for pharmaceuticals or quasi-drugs and are pharmacologically acceptable. One or more of antioxidants, coloring agents and the like can be mentioned. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like.
本発明の組成物を飼料とする場合には、エルゴチオネイン又はその塩及びエイコサペンタエン酸類を飼料に配合すればよい。飼料には飼料添加剤も含まれる。飼料としては、例えば、牛、豚、鶏、羊、馬等に用いる家畜用飼料；ウサギ、ラット、マウス等に用いる小動物用飼料；犬、猫、小鳥等に用いるペットフードなどが挙げられる。
When the composition of the present invention is used as a feed, ergothioneine or a salt thereof and eicosapentaenoic acids may be added to the feed. Feed also includes feed additives. Examples of feeds include livestock feeds for cows, pigs, chickens, sheep, horses, etc.; small animal feeds for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.;
本発明の組成物を摂取させる又は投与する対象（投与対象ということもできる）は、特に限定されない。好ましくはヒト又は非ヒト哺乳動物であり、より好ましくはヒトである。
Subjects to whom the composition of the present invention is ingested or administered (can also be referred to as administration subjects) are not particularly limited. Humans or non-human mammals are preferred, and humans are more preferred.
本発明は、以下の方法も包含する。
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有する経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を０．５～１５に調整する、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法。
上記の方法により、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する不快な香味（臭み）を効果的に抑制することが可能となる。 The present invention also includes the following methods.
In the preparation of an oral composition containing (A) ergothioneine or a salt thereof and (B) at least one eicosapentaenoic acid, component (B) (eicosapentaenoic acid equivalent) relative to component (A) (ergothioneine equivalent) A method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids by adjusting the weight ratio ((B)/(A)) of 0.5 to 15.
By the above method, bitterness derived from ergothioneine or a salt thereof and unpleasant flavor (smell) derived from eicosapentaenoic acids can be effectively suppressed.
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）少なくとも１種のエイコサペンタエン酸類、を含有する経口組成物の調製において、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を０．５～１５に調整する、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法。
上記の方法により、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する不快な香味（臭み）を効果的に抑制することが可能となる。 The present invention also includes the following methods.
In the preparation of an oral composition containing (A) ergothioneine or a salt thereof and (B) at least one eicosapentaenoic acid, component (B) (eicosapentaenoic acid equivalent) relative to component (A) (ergothioneine equivalent) A method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids by adjusting the weight ratio ((B)/(A)) of 0.5 to 15.
By the above method, bitterness derived from ergothioneine or a salt thereof and unpleasant flavor (smell) derived from eicosapentaenoic acids can be effectively suppressed.
本発明は、以下の使用も包含する。
少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用。
上記の使用において、エルゴチオネイン又はその塩（エルゴチオネイン換算）に対する少なくとも１種のエイコサペンタエン酸類（エイコサペンタエン酸換算）の重量比が０．５～１５となるように使用することが好ましい。 The present invention also includes the following uses.
Use of at least one eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof.
In the above use, the weight ratio of at least one eicosapentaenoic acid (eicosapentaenoic acid conversion) to ergothioneine or a salt thereof (ergothioneine conversion) is preferably 0.5-15.
少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用。
上記の使用において、エルゴチオネイン又はその塩（エルゴチオネイン換算）に対する少なくとも１種のエイコサペンタエン酸類（エイコサペンタエン酸換算）の重量比が０．５～１５となるように使用することが好ましい。 The present invention also includes the following uses.
Use of at least one eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof.
In the above use, the weight ratio of at least one eicosapentaenoic acid (eicosapentaenoic acid conversion) to ergothioneine or a salt thereof (ergothioneine conversion) is preferably 0.5-15.
上記の方法及び使用において、エルゴチオネイン又はその塩及びエイコサペンタエン酸類並びにそれらの好ましい態様は、上述した本発明の組成物と同じである。
また、上記の方法及び使用において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲も、本発明の組成物における、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲と同じである。 In the methods and uses described above, ergothioneine or salts thereof and eicosapentaenoic acids and preferred embodiments thereof are the same as the compositions of the present invention described above.
In the above method and use, the preferred range of the weight ratio and amount of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is also determined by component (A) in the composition of the present invention. ) (converted to ergothioneine) and the weight ratio of component (B) (converted to eicosapentaenoic acid) and the preferred range of the amount used.
また、上記の方法及び使用において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲も、本発明の組成物における、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比や使用量の好ましい範囲と同じである。 In the methods and uses described above, ergothioneine or salts thereof and eicosapentaenoic acids and preferred embodiments thereof are the same as the compositions of the present invention described above.
In the above method and use, the preferred range of the weight ratio and amount of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is also determined by component (A) in the composition of the present invention. ) (converted to ergothioneine) and the weight ratio of component (B) (converted to eicosapentaenoic acid) and the preferred range of the amount used.
上記の方法及び使用によって、エルゴチオネイン又はその塩に由来する苦味及びＥＰＡに由来する臭みを抑制することができるが、他の苦味抑制方法及び／又は臭み抑制方法と組み合わせてもよい。
他の苦味抑制方法としては、例えば、苦味を有する成分に甘味剤又は矯味剤を添加して製剤化する方法、苦味を有する成分を糖衣で被覆して製剤化する方法、又はカプセルに封入して製剤化する方法等が挙げられる。
他の臭み抑制方法としては、例えば、臭みを有する成分を糖衣で被覆して製剤化する方法、カプセルに封入して製剤化する方法等が挙げられる。 Although the bitterness derived from ergothioneine or a salt thereof and the odor derived from EPA can be suppressed by the above methods and uses, they may be combined with other bitterness suppression methods and/or odor suppression methods.
Other methods for suppressing bitterness include, for example, a method of adding a sweetening agent or a corrigent to a bitter component to prepare a formulation, a method of coating a bitter component with sugar coating to form a formulation, or encapsulating the bitter component into a capsule. A method of formulation and the like can be mentioned.
Other odor-suppressing methods include, for example, a method of coating an odorous component with sugar coating to form a formulation, and a method of enclosing in a capsule to form a formulation.
他の苦味抑制方法としては、例えば、苦味を有する成分に甘味剤又は矯味剤を添加して製剤化する方法、苦味を有する成分を糖衣で被覆して製剤化する方法、又はカプセルに封入して製剤化する方法等が挙げられる。
他の臭み抑制方法としては、例えば、臭みを有する成分を糖衣で被覆して製剤化する方法、カプセルに封入して製剤化する方法等が挙げられる。 Although the bitterness derived from ergothioneine or a salt thereof and the odor derived from EPA can be suppressed by the above methods and uses, they may be combined with other bitterness suppression methods and/or odor suppression methods.
Other methods for suppressing bitterness include, for example, a method of adding a sweetening agent or a corrigent to a bitter component to prepare a formulation, a method of coating a bitter component with sugar coating to form a formulation, or encapsulating the bitter component into a capsule. A method of formulation and the like can be mentioned.
Other odor-suppressing methods include, for example, a method of coating an odorous component with sugar coating to form a formulation, and a method of enclosing in a capsule to form a formulation.
本明細書において下限値と上限値によって表されている数値範囲、即ち「下限値～上限値」は、それら下限値及び上限値を含む。例えば、「１～２」により表される範囲は、１以上２以下を意味し、１及び２を含む。本明細書において、上限及び下限は、いずれの組み合わせによる範囲としてもよい。
Numerical ranges represented by lower and upper limits herein, ie, "lower and upper limits", include these lower and upper limits. For example, a range represented by "1-2" means from 1 to 2 and includes 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.
以下、本発明を実施例に基づいてより具体的に説明する。尚、本発明はこれらの実施例に限定されるものではない。
EXAMPLES The present invention will be described in more detail below based on examples. However, the present invention is not limited to these examples.
下記の評価試験で使用した材料は以下のとおりである。
（Ａ）エルゴチオネイン：Ｌ－エルゴチオネイン１００％含有原料
エイコサペンタエン酸類含有油脂：エイコサペンタエン酸類をエイコサペンタエン酸換算で２０重量％含有し、構成脂肪酸の中で、ｎ－３系脂肪酸についてはＥＰＡの重量割合が最も高い油脂 Materials used in the following evaluation tests are as follows.
(A) Ergothioneine: Raw material containing 100% L-ergothioneine Eicosapentaenoic acids-containing oil: Contains 20% by weight of eicosapentaenoic acids in terms of eicosapentaenoic acid, and among the constituent fatty acids, the weight ratio of EPA for n-3 fatty acids fat with the highest
（Ａ）エルゴチオネイン：Ｌ－エルゴチオネイン１００％含有原料
エイコサペンタエン酸類含有油脂：エイコサペンタエン酸類をエイコサペンタエン酸換算で２０重量％含有し、構成脂肪酸の中で、ｎ－３系脂肪酸についてはＥＰＡの重量割合が最も高い油脂 Materials used in the following evaluation tests are as follows.
(A) Ergothioneine: Raw material containing 100% L-ergothioneine Eicosapentaenoic acids-containing oil: Contains 20% by weight of eicosapentaenoic acids in terms of eicosapentaenoic acid, and among the constituent fatty acids, the weight ratio of EPA for n-3 fatty acids fat with the highest
＜実施例１～３及び比較例１～２：エルゴチオネイン及びエイコサペンタエン酸類を含む経口組成物についての香味評価試験＞
エルゴチオネイン及びエイコサペンタエン酸類を含む経口組成物を調製し、官能評価に熟練したパネラー３名が官能評価を行った。
表１に示す量の上記（Ａ）及びエイコサペンタエン酸類含有油脂を使用して、実施例１～３及び比較例１～２の経口組成物を調製した。各経口組成物中の（Ａ）エルゴチオネイン及びエイコサペンタエン酸類含有油脂の量、（Ｂ）エイコサペンタエン酸類（エイコサペンタエン酸換算）の含有量、（Ａ）エルゴチオネインに対する（Ｂ）エイコサペンタエン酸類（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を表１に示す。
各パネラーが、調製した経口組成物の全量（例えば、比較例１では２０ｍｇ）を直接舌の上にのせて、エルゴチオネイン由来の苦味の強度及びエイコサペンタエン酸類由来の臭みの強度を以下の基準にしたがって評価した。 <Examples 1-3 and Comparative Examples 1-2: Flavor evaluation test for oral compositions containing ergothioneine and eicosapentaenoic acids>
An oral composition containing ergothioneine and eicosapentaenoic acids was prepared, and sensory evaluation was performed by three panelists skilled in sensory evaluation.
Oral compositions of Examples 1 to 3 and Comparative Examples 1 and 2 were prepared using the above (A) and eicosapentaenoic acid-containing fats and oils in the amounts shown in Table 1. (A) Amount of ergothioneine and eicosapentaenoic acid-containing fats and oils in each oral composition, (B) content of eicosapentaenoic acids (eicosapentaenoic acid conversion), (B) eicosapentaenoic acids (eicosapentaenoic acid) relative to (A) ergothioneine conversion) weight ratio ((B)/(A)) is shown in Table 1.
Each panelist placed the total amount of the prepared oral composition (e.g., 20 mg in Comparative Example 1) directly on the tongue, and measured the intensity of bitterness derived from ergothioneine and the intensity of odor derived from eicosapentaenoic acids according to the following criteria. evaluated.
エルゴチオネイン及びエイコサペンタエン酸類を含む経口組成物を調製し、官能評価に熟練したパネラー３名が官能評価を行った。
表１に示す量の上記（Ａ）及びエイコサペンタエン酸類含有油脂を使用して、実施例１～３及び比較例１～２の経口組成物を調製した。各経口組成物中の（Ａ）エルゴチオネイン及びエイコサペンタエン酸類含有油脂の量、（Ｂ）エイコサペンタエン酸類（エイコサペンタエン酸換算）の含有量、（Ａ）エルゴチオネインに対する（Ｂ）エイコサペンタエン酸類（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を表１に示す。
各パネラーが、調製した経口組成物の全量（例えば、比較例１では２０ｍｇ）を直接舌の上にのせて、エルゴチオネイン由来の苦味の強度及びエイコサペンタエン酸類由来の臭みの強度を以下の基準にしたがって評価した。 <Examples 1-3 and Comparative Examples 1-2: Flavor evaluation test for oral compositions containing ergothioneine and eicosapentaenoic acids>
An oral composition containing ergothioneine and eicosapentaenoic acids was prepared, and sensory evaluation was performed by three panelists skilled in sensory evaluation.
Oral compositions of Examples 1 to 3 and Comparative Examples 1 and 2 were prepared using the above (A) and eicosapentaenoic acid-containing fats and oils in the amounts shown in Table 1. (A) Amount of ergothioneine and eicosapentaenoic acid-containing fats and oils in each oral composition, (B) content of eicosapentaenoic acids (eicosapentaenoic acid conversion), (B) eicosapentaenoic acids (eicosapentaenoic acid) relative to (A) ergothioneine conversion) weight ratio ((B)/(A)) is shown in Table 1.
Each panelist placed the total amount of the prepared oral composition (e.g., 20 mg in Comparative Example 1) directly on the tongue, and measured the intensity of bitterness derived from ergothioneine and the intensity of odor derived from eicosapentaenoic acids according to the following criteria. evaluated.
（エルゴチオネイン由来の苦味の評価基準）
下記の基準で１～５点（５段階）で評価した。基準点として、材料（Ａ）（１０ｍｇ）を舌の上にのせた場合に感じられたエルゴチオネイン由来の苦味の強度を５点とした。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
評価結果の平均値が４点以下の場合に苦味が抑制されたと評価した。
５点：エルゴチオネイン由来の苦味を強く感じる
４点：エルゴチオネイン由来の苦味を感じる
３点：エルゴチオネイン由来の苦味を少し感じる
２点：エルゴチオネイン由来の苦味をあまり感じない
１点：エルゴチオネイン由来の苦味を感じない (Evaluation criteria for bitterness derived from ergothioneine)
Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the strength of the bitterness derived from ergothioneine felt when material (A) (10 mg) was placed on the tongue was rated as 5 points.
Table 1 shows the average values (scores) of the evaluations of the three panelists.
When the average value of the evaluation results was 4 points or less, it was evaluated that the bitterness was suppressed.
5 points: feel the bitterness derived from ergothioneine strongly 4 points: feel the bitterness derived from ergothioneine 3 points: feel the bitterness derived from ergothioneine a little 2 points: do not feel the bitterness derived from ergothioneine much 1 point: do not feel the bitterness derived from ergothioneine
下記の基準で１～５点（５段階）で評価した。基準点として、材料（Ａ）（１０ｍｇ）を舌の上にのせた場合に感じられたエルゴチオネイン由来の苦味の強度を５点とした。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
評価結果の平均値が４点以下の場合に苦味が抑制されたと評価した。
５点：エルゴチオネイン由来の苦味を強く感じる
４点：エルゴチオネイン由来の苦味を感じる
３点：エルゴチオネイン由来の苦味を少し感じる
２点：エルゴチオネイン由来の苦味をあまり感じない
１点：エルゴチオネイン由来の苦味を感じない (Evaluation criteria for bitterness derived from ergothioneine)
Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the strength of the bitterness derived from ergothioneine felt when material (A) (10 mg) was placed on the tongue was rated as 5 points.
Table 1 shows the average values (scores) of the evaluations of the three panelists.
When the average value of the evaluation results was 4 points or less, it was evaluated that the bitterness was suppressed.
5 points: feel the bitterness derived from ergothioneine strongly 4 points: feel the bitterness derived from ergothioneine 3 points: feel the bitterness derived from ergothioneine a little 2 points: do not feel the bitterness derived from ergothioneine much 1 point: do not feel the bitterness derived from ergothioneine
（エイコサペンタエン酸類由来の臭みの評価基準）
下記の基準で１～５点（５段階）で評価した。基準点として、エイコサペンタエン酸含有油脂（１０ｍｇ）を舌の上にのせた場合に感じられたエイコサペンタエン酸類由来の臭みの強度を５点とした。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
評価結果の平均値が４点以下の場合に臭みが抑制されたと評価した。
５点：エイコサペンタエン酸類由来の臭みを強く感じる
４点：エイコサペンタエン酸類由来の臭みを感じる
３点：エイコサペンタエン酸類由来の臭みを少し感じる
２点：エイコサペンタエン酸類由来の臭みをあまり感じない
１点：エイコサペンタエン酸類由来の臭みを感じない (Evaluation Criteria for Odor Derived from Eicosapentaenoic Acids)
Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the strength of the odor derived from eicosapentaenoic acids felt when the eicosapentaenoic acid-containing oil (10 mg) was placed on the tongue was rated as 5 points.
Table 1 shows the average values (scores) of the evaluations of the three panelists.
When the average value of the evaluation results was 4 points or less, it was evaluated that the odor was suppressed.
5 points: strongly feel the odor derived from eicosapentaenoic acids 4 points: feel the odor derived from eicosapentaenoic acids 3 points: slightly feel the odor derived from eicosapentaenoic acids 2 points: 1 point not much feel the odor derived from eicosapentaenoic acids : No odor derived from eicosapentaenoic acids
下記の基準で１～５点（５段階）で評価した。基準点として、エイコサペンタエン酸含有油脂（１０ｍｇ）を舌の上にのせた場合に感じられたエイコサペンタエン酸類由来の臭みの強度を５点とした。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
評価結果の平均値が４点以下の場合に臭みが抑制されたと評価した。
５点：エイコサペンタエン酸類由来の臭みを強く感じる
４点：エイコサペンタエン酸類由来の臭みを感じる
３点：エイコサペンタエン酸類由来の臭みを少し感じる
２点：エイコサペンタエン酸類由来の臭みをあまり感じない
１点：エイコサペンタエン酸類由来の臭みを感じない (Evaluation Criteria for Odor Derived from Eicosapentaenoic Acids)
Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the strength of the odor derived from eicosapentaenoic acids felt when the eicosapentaenoic acid-containing oil (10 mg) was placed on the tongue was rated as 5 points.
Table 1 shows the average values (scores) of the evaluations of the three panelists.
When the average value of the evaluation results was 4 points or less, it was evaluated that the odor was suppressed.
5 points: strongly feel the odor derived from eicosapentaenoic acids 4 points: feel the odor derived from eicosapentaenoic acids 3 points: slightly feel the odor derived from eicosapentaenoic acids 2 points: 1 point not much feel the odor derived from eicosapentaenoic acids : No odor derived from eicosapentaenoic acids
＜結果＞
エルゴチオネインのみの場合、エルゴチオネイン由来の強い苦みが感じられたが、（Ａ）エルゴチオネインと（Ｂ）エイコサペンタエン酸類（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が０．５～１５の範囲内であると、エルゴチオネイン由来の苦味が抑制されることを確認した。エイコサペンタエン酸類についても、エイコサペンタエン酸類を含有する油脂のみではエイコサペンタエン酸類に由来する臭みが強く摂取しにくいが、上記の重量比でエルゴチオネインと組み合わせることにより、エイコサペンタエン酸類に由来する臭みが抑制されることを確認した。
<Results>
In the case of ergothioneine alone, a strong bitterness derived from ergothioneine was felt, but the weight ratio ((B) / (A)) of (A) ergothioneine and (B) eicosapentaenoic acids (eicosapentaenoic acid conversion) was 0.5 to It was confirmed that the bitterness derived from ergothioneine is suppressed within the range of 15. With regard to eicosapentaenoic acids, it is difficult to ingest only fats and oils containing eicosapentaenoic acids due to the strong odor derived from eicosapentaenoic acids. I was sure that.
エルゴチオネインのみの場合、エルゴチオネイン由来の強い苦みが感じられたが、（Ａ）エルゴチオネインと（Ｂ）エイコサペンタエン酸類（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が０．５～１５の範囲内であると、エルゴチオネイン由来の苦味が抑制されることを確認した。エイコサペンタエン酸類についても、エイコサペンタエン酸類を含有する油脂のみではエイコサペンタエン酸類に由来する臭みが強く摂取しにくいが、上記の重量比でエルゴチオネインと組み合わせることにより、エイコサペンタエン酸類に由来する臭みが抑制されることを確認した。
<Results>
In the case of ergothioneine alone, a strong bitterness derived from ergothioneine was felt, but the weight ratio ((B) / (A)) of (A) ergothioneine and (B) eicosapentaenoic acids (eicosapentaenoic acid conversion) was 0.5 to It was confirmed that the bitterness derived from ergothioneine is suppressed within the range of 15. With regard to eicosapentaenoic acids, it is difficult to ingest only fats and oils containing eicosapentaenoic acids due to the strong odor derived from eicosapentaenoic acids. I was sure that.
Claims (8)
- 下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、
（Ｂ）少なくとも１種のエイコサペンタエン酸類、
を含有し、
成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が０．５～１５である、経口組成物。 Components (A) and (B) below:
(A) ergothioneine or a salt thereof, and
(B) at least one eicosapentaenoic acid;
contains
An oral composition, wherein the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5 to 15. - 前記エイコサペンタエン酸類が、遊離のエイコサペンタエン酸、その塩及びエイコサペンタエン酸を構成脂肪酸に含む化合物からなる群より選択される、請求項１に記載の組成物。 2. The composition according to claim 1, wherein said eicosapentaenoic acids are selected from the group consisting of free eicosapentaenoic acid, salts thereof and compounds containing eicosapentaenoic acid as a constituent fatty acid.
- 前記エイコサペンタエン酸を構成脂肪酸に含む化合物が、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるトリグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるジグリセリド、構成脂肪酸がエイコサペンタエン酸であるモノグリセリド、構成脂肪酸の一部又は全部がエイコサペンタエン酸であるリン脂質、構成脂肪酸の一部又は全部がエイコサペンタエン酸である糖脂質及びエイコサペンタエン酸のアルコールエステルからなる群より選択される、請求項２に記載の組成物。 The compound containing eicosapentaenoic acid as a constituent fatty acid is a triglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, a diglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, and the constituent fatty acid is eicosapentaenoic acid. Selected from the group consisting of monoglycerides, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid. 2. The composition according to 2.
- 成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））が、２～２０である、請求項１～３のいずれか１項に記載の組成物。 The weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 2 to 20, according to any one of claims 1 to 3. The described composition.
- 成分（Ｂ）が、魚介類由来である、請求項１～３のいずれか１項に記載の組成物。 The composition according to any one of claims 1 to 3, wherein component (B) is derived from seafood.
- 飲食品である、請求項１～３のいずれか１項に記載の組成物。 The composition according to any one of claims 1 to 3, which is a food or drink.
- 少なくとも１種のエイコサペンタエン酸類の、エルゴチオネイン又はその塩に由来する苦味を抑制するための使用。 Use of at least one eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof.
- （Ａ）エルゴチオネイン又はその塩、及び、
（Ｂ）少なくとも１種のエイコサペンタエン酸類、
を含有する経口組成物の調製において、
成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）（エイコサペンタエン酸換算）の重量比（（Ｂ）／（Ａ））を０．５～１５に調整する、エルゴチオネイン又はその塩に由来する苦味及びエイコサペンタエン酸類に由来する臭みを抑制する方法。
(A) ergothioneine or a salt thereof, and
(B) at least one eicosapentaenoic acid;
In the preparation of an oral composition containing
Bitterness derived from ergothioneine or a salt thereof, wherein the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid conversion) to component (A) (ergothioneine conversion) is adjusted to 0.5 to 15 A method for suppressing an odor derived from eicosapentaenoic acids.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021209560 | 2021-12-23 | ||
| JP2021-209560 | 2021-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023120368A1 true WO2023120368A1 (en) | 2023-06-29 |
Family
ID=86902472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/046213 WO2023120368A1 (en) | 2021-12-23 | 2022-12-15 | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW202342005A (en) |
| WO (1) | WO2023120368A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0731417A (en) * | 1993-07-20 | 1995-02-03 | Health Eido:Kk | Encapsulated nutrient-assisting food |
| JP2012092085A (en) * | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| US20120128711A1 (en) * | 2009-09-21 | 2012-05-24 | Total Nutraceutical Solutions, Inc. | Anti-inflammatory approach to prevention and suppression of post-traumatic stress disorder, traumatic brain injury, depression and associated disease states |
| US20150157648A1 (en) * | 2012-06-26 | 2015-06-11 | Entia Biosciences, Inc. | Nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
-
2022
- 2022-12-15 WO PCT/JP2022/046213 patent/WO2023120368A1/en unknown
- 2022-12-22 TW TW111149416A patent/TW202342005A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0731417A (en) * | 1993-07-20 | 1995-02-03 | Health Eido:Kk | Encapsulated nutrient-assisting food |
| US20120128711A1 (en) * | 2009-09-21 | 2012-05-24 | Total Nutraceutical Solutions, Inc. | Anti-inflammatory approach to prevention and suppression of post-traumatic stress disorder, traumatic brain injury, depression and associated disease states |
| JP2012092085A (en) * | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| US20150157648A1 (en) * | 2012-06-26 | 2015-06-11 | Entia Biosciences, Inc. | Nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
Non-Patent Citations (1)
| Title |
|---|
| ANONYMOUS: "A comparative quantitative analysis of ergothioneine contained in mushrooms", MST TECHNICAL DOCUMENT. FOUNDATION FOR PROMOTION OF MATERIAL SCIENCE AND TECHNOLOGY OF JAPAN., 30 April 2014 (2014-04-30), XP093074187, Retrieved from the Internet <URL:https://www.mst.or.jp/Portals/0/case/pdf/c0345.pdf> [retrieved on 20230816] * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202342005A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2006093267A1 (en) | Fermentation composition having immunomodulatory action | |
| WO2014098193A1 (en) | Pet food | |
| JPWO2007000985A1 (en) | Composition for preventing or treating hemoglobinuria or myoglobinuria | |
| TWI389697B (en) | Improve the composition of lipid metabolism | |
| WO2006033355A1 (en) | Oral pharmaceutical for dry skin prevention or remedy | |
| JP4776163B2 (en) | Colon cancer inhibitor and food containing the same | |
| WO2023120368A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid | |
| JP2677949B2 (en) | Health food containing arachidonic acid | |
| WO2023120373A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid | |
| WO2023120378A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and smell derived from arachidonic acids | |
| JP6252922B2 (en) | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof | |
| AU2022420208A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid | |
| AU2022420207A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid | |
| AU2022420209A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and smell derived from arachidonic acids | |
| RU2284707C1 (en) | Bioactive food supplement | |
| JP6024942B2 (en) | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof | |
| WO2024029393A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material | |
| JP4873605B2 (en) | A composition having an angiogenesis-inhibiting action comprising a cereal-derived ingredient as an active ingredient | |
| WO2024018956A1 (en) | Oral composition, and method for suppressing bitterness originating from ergothioneine or salt thereof and odor originating from chondroitin sulfate or salt thereof | |
| WO2023120370A1 (en) | Oral composition and method for minimizing bitter taste resulting from ergothioneine or salt thereof and odor resulting from vitamin e | |
| WO2024018955A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound | |
| WO2023120367A1 (en) | Oral composition and method for suppressing bitterness derived from ergothioneine | |
| WO2022230491A1 (en) | Composition for ameliorating or suppressing decline of kidney functions | |
| AU2022423515A1 (en) | Oral composition and method for minimizing bitter taste resulting from ergothioneine or salt thereof and odor resulting from vitamin e | |
| WO2023120382A1 (en) | Oral composition and soft capsule agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22911076 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2023569372 Country of ref document: JP Kind code of ref document: A |